Point72 Asia Singapore Pte. Ltd. Takes $104,000 Position in Inari Medical, Inc. (NASDAQ:NARI)

Point72 Asia Singapore Pte. Ltd. acquired a new position in Inari Medical, Inc. (NASDAQ:NARI) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,159 shares of the company’s stock, valued at approximately $104,000.

A number of other hedge funds have also bought and sold shares of NARI. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Inari Medical in the first quarter worth approximately $30,000. GAMMA Investing LLC grew its position in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC raised its stake in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after buying an additional 435 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after buying an additional 376 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

NARI has been the subject of a number of research reports. Stifel Nicolaus started coverage on Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective for the company. Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. William Blair started coverage on shares of Inari Medical in a report on Thursday, July 25th. They issued an “outperform” rating on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $50.00 target price on shares of Inari Medical in a report on Monday, August 26th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Inari Medical in a research note on Friday, August 9th. They set a “buy” rating and a $68.00 price target on the stock. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $58.44.

Insider Activity at Inari Medical

In other Inari Medical news, insider Thomas Tu sold 16,520 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $55.09, for a total value of $910,086.80. Following the completion of the transaction, the insider now directly owns 313,257 shares in the company, valued at $17,257,328.13. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Mitch C. Hill sold 5,000 shares of Inari Medical stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $53.95, for a total value of $269,750.00. Following the sale, the chief financial officer now directly owns 179,227 shares of the company’s stock, valued at approximately $9,669,296.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Tu sold 16,520 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $55.09, for a total value of $910,086.80. Following the completion of the sale, the insider now owns 313,257 shares in the company, valued at $17,257,328.13. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 132,520 shares of company stock valued at $6,958,467. 10.60% of the stock is owned by company insiders.

Inari Medical Price Performance

Shares of NARI stock opened at $41.92 on Friday. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $69.40. The company’s fifty day moving average price is $45.27 and its 200-day moving average price is $46.07. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -102.24 and a beta of 1.00.

Inari Medical (NASDAQ:NARI) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The business had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. Equities research analysts expect that Inari Medical, Inc. will post -0.7 earnings per share for the current fiscal year.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.